Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
盖利艾德股价正在上涨，因公司宣布了第三阶段试验的中期结果，显示每年两次使用Lenacapavir将HIV感染率降低了96%。
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
吉利德公司公布了3期试验的中期业绩，显示每年两次的来那卡韦将艾滋病毒感染率降低了96％，此后，吉利德股价走高。
资讯热榜
更新时间